Literature DB >> 22903889

Immune-mediated disorders among women carriers of fragile X premutation alleles.

Tri Indah Winarni1, Weerasak Chonchaiya, Tanjung Ayu Sumekar, Paul Ashwood, Guadalupe Mendoza Morales, Flora Tassone, Danh V Nguyen, Sultana M H Faradz, Judy Van de Water, Kylee Cook, Alyssa Hamlin, Yi Mu, Paul J Hagerman, Randi J Hagerman.   

Abstract

The relative risk of immune-mediated disorders (IMDs) among women carriers of premutation alleles is estimated by a survey for IMDs among 344 carrier women (age 19-81 years; mean 46.35 and SD 12.60) and 72 controls (age 18-87 years; mean 52.40 and SD 15.40). One hundred fifty four (44.77%) women carrier had at least one IMD, as did 20 controls (27.78%). Among women carriers, autoimmune thyroid disorder was the most common (24.4%), then fibromyalgia (10.2%), irritable bowel syndrome (IBS; 9.9%), Raynaud's phenomenon (7.6%), rheumatoid arthritis (RA; 3.8%), Sjögren syndrome (2.6%), systemic lupus erythematosus (SLE; 2.03%), multiple sclerosis (1.74%). Of 55 carriers age 40 or older with FXTAS, 72.73% had at least one IMD, compared to 46.54% of those without FXTAS (n = 159), and 31.58% of controls (n = 57). The estimated odds ratio (OR) for IMD is 2.6 (95% CI 1.2-5.6, P = 0.015) for women with FXTAS relative to those without FXTAS; the likelihood of IMD in carriers without or with FXTAS was also significantly higher than for controls (OR 2.1, 95% CI 1.1-4.2, P = 0.034; OR 5.5, 95% CI 2.4-12.5, P < 0.001, respectively). Similarly, the odds of having an IMD among carriers with FXPOI is about 2.4 times higher when compared to carriers without FXPOI (95% CI 1.1-5.0; P = 0.021). The likelihood of IMD in carriers with or without FXPOI is greater (OR 2.4, 95% CI 1.1-5.0; P = 0.021) compared to that of controls.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903889      PMCID: PMC4105154          DOI: 10.1002/ajmg.a.35569

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  59 in total

1.  The prevalence of rheumatoid arthritis in the general population of Spain.

Authors:  L Carmona; V Villaverde; C Hernández-García; J Ballina; R Gabriel; A Laffon
Journal:  Rheumatology (Oxford)       Date:  2002-01       Impact factor: 7.580

2.  Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data.

Authors:  M L Uzielli; S Guarducci; E Lapi; A Cecconi; U Ricci; G Ricotti; C Biondi; B Scarselli; F Vieri; P Scarnato; F Gori; A Sereni
Journal:  Am J Med Genet       Date:  1999-05-28

Review 3.  Epidemiology of connective tissue disorders.

Authors:  M Gaubitz
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

4.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

5.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

Review 6.  FXTAS: a bad RNA and a hope for a cure.

Authors:  Ge Shan; Shunliang Xu; Peng Jin
Journal:  Expert Opin Biol Ther       Date:  2008-03       Impact factor: 4.388

7.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

Review 8.  Toll-like receptors and T-helper-1/T-helper-2 responses.

Authors:  Karim Dabbagh; David B Lewis
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

9.  Prevalence of fibromyalgia: a survey in five European countries.

Authors:  Jaime C Branco; Bernard Bannwarth; Inmaculada Failde; Jordi Abello Carbonell; Francis Blotman; Michael Spaeth; Fernando Saraiva; Francesca Nacci; Eric Thomas; Jean-Paul Caubère; Katell Le Lay; Charles Taieb; Marco Matucci-Cerinic
Journal:  Semin Arthritis Rheum       Date:  2009-02-27       Impact factor: 5.532

Review 10.  Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems.

Authors:  Randi J Hagerman; Deborah A Hall; Sarah Coffey; Maureen Leehey; James Bourgeois; John Gould; Lin Zhang; Andreea Seritan; Elizabeth Berry-Kravis; John Olichney; Joshua W Miller; Amy L Fong; Randall Carpenter; Cathy Bodine; Louise W Gane; Edgar Rainin; Hillary Hagerman; Paul J Hagerman
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more
  51 in total

1.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 3.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

4.  Methadone use in a male with the FMRI premutation and FXTAS.

Authors:  Zukhrofi Muzar; Reymundo Lozano; Andrea Schneider; Patrick E Adams; Sultana M H Faradz; Flora Tassone; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2015-04-21       Impact factor: 2.802

Review 5.  The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.

Authors:  Jim Grigsby
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 6.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

Review 7.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

8.  Prevalence and risk of migraine headaches in adult fragile X premutation carriers.

Authors:  J Au; R S Akins; L Berkowitz-Sutherland; H-T Tang; Y Chen; A Boyd; F Tassone; D V Nguyen; R Hagerman
Journal:  Clin Genet       Date:  2013-02-21       Impact factor: 4.438

Review 9.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

Review 10.  Fragile X syndrome: A review of clinical management.

Authors:  Reymundo Lozano; Atoosa Azarang; Tanaporn Wilaisakditipakorn; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.